Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocuronium-sugammadex versus succinylcholine for myalgia and headache after electroconvulsive therapy
ACTRN12613000054718Phase 4Completed
- Sponsor
- Gaziantep University
- Start
- Feb 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 4, open-label trial of rocuronium, Sugammadex, succinylcholine and propofol in major depressive disorder (MDD) (2 arms), sponsored by Gaziantep University. Primary endpoints: Visual analogue scale myalgia after ECT and Visual analogue scale headache after ECT. Started Feb 2012; status: completed.
02
Drugs
rocuroniumSugammadexsuccinylcholinepropofol
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12613000054718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000054718.